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Human biomonitoring (HBM) depends on high-quality human samples to identify status and trends in exposure
and ensure comparability of results. In this context, much effort has been put into the development of stan-
dardized processes and quality assurance for sampling and chemical analysis, while effects of sample storage
and shipment on sample quality have been less thoroughly addressed. To characterize the currently applied
storage and shipment procedures within the consortium of the European Human Biomonitoring Initiative
(HBM4EU), which aims at harmonization of HBM in Europe, a requirement analysis based on data from an
online survey was conducted. In addition, the online survey was addressed to professionals in clinical bio-
banking represented by members of the European, Middle Eastern and African Society for Biopreservation and
Biobanking (ESBB) to identify the current state-of-the-art in terms of sample storage and shipment. Results of
this survey conducted in these two networks were compared to detect processes with potential for optimization
and harmonization. In general, many similarities exist in sample storage and shipment procedures applied by
ESBB members and HBM4EU partners and many requirements for ensuring sample quality are already
met also by HBM4EU partners. Nevertheless, a need for improvement was identified for individual steps in
sample storage, shipment, and related data management with potential impact on sample and data quality for
HBM purposes. Based on these findings, recommendations for crucial first steps to further strengthen sample
quality, and thus foster advancement in HBM on a pan-European level are given.
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Human biomonitoring, the analysis of human sam-ples for exposure to chemicals and/or their metabolites,
provides a scientific basis for risk assessment and, if nec-
essary, the derivation of mitigation measures. At a European
scale, comparable and reliable data on human exposure from
European Union countries are urgently needed. The Euro-
pean Initiative for Human Biomonitoring (HBM4EU) star-
ted work on January 1, 2017, to close data gaps on priority
environmental pollutants in the European population and to
provide sound scientific data as a basis for policy decisions.
HBM4EU, co-funded under Horizon 2020, is a joint project
of 30 mainly European countries, the European Environ-
ment Agency, and the European Commission. One of the
aims of the initiative is the harmonization of preanalytical
and analytical processes in human biomonitoring (HBM)
across Europe and to increase knowledge transfer between
scientists, politicians, stakeholders, and the general pub-
lic.1–3 Several European countries have been conducting
HBM studies during the last decades, whereas such studies
are still lacking in others. Since a full characterization of all
substances humans are exposed to is not feasible, studies
(e.g., from Germany, France, Spain, Czech Republic, Bel-
gium, and Slovenia) have been covering only a selected
number of environmental pollutants at the time.4 Therefore,
previous HBM studies differ largely between individual
countries pertaining to the target population, questionnaires,
matrices, and analytes. First, endeavors toward the harmo-
nization of HBM research across Europe were made in the
projects COPHES and DEMOCOPHES.5,6 For the first time,
samples from 120 mother-child pairs were collected in 17
European countries following a consensus protocol de-
scribing harmonized sampling and preparation, common
questionnaires, and data analysis among others. Six bio-
markers (mercury, creatinine, cotinine, cadmium, phthalate
metabolites, and bisphenol A)4 were analyzed according to
standardized protocols and strong quality assurance (QA)/
quality control (QC) measures. A quality assurance unit
(QAU) was set up to guarantee the reliability and compa-
rability of analytical results. The QAU implemented an
Inter-laboratory Comparison Investigation and External
Quality Assessment Schemes (ICI/EQUAS) program in-
volving reference laboratories from all over the world5,7
Biobanking, the short- and long-term storage of human
samples under cryogenic conditions, plays a critical role in
the preanalytical phase of HBM studies. In contrast to what
has long been happening in medical research, where bio-
banking and related preanalytical processes have been
playing an important role for many years, in HBM, the
relevance of using standardized biobanking procedures has
only been recognized in the last 10 years. Therefore, a
transfer of the well-established methods and standards,
which are already in place in medical research, would be
beneficial for the emerging field of HBM research.
Although several online surveys have been conducted to
address missing knowledge on the extent of biobanking in
Europe, HBM-specific biobanking activities have not been
included so far.8–10 The HBM4EU initiative comprises im-
portant HBM key players in Europe, and hence offers a
unique opportunity to gather knowledge on harmonization
and optimization needs to improve HBM-related biobank-
ing. In this context, we conducted a requirement analysis
regarding sample storage and sample shipment through an
online questionnaire addressed to all HBM4EU partners. In
addition, the current state-of-the-art methods for sample
storage and shipment as applied by professionals in clinical
biobanking were assessed by an online questionnaire ad-
dressed to members of the European, Middle Eastern and
African Society for Biopreservation and Biobanking
(ESBB). ESBB provides a scientific network to advance
BIOSHARING for a better world through mobilizing, in-
spiring, and educating the biobank community across Eur-
ope, Middle Eastern, and Africa. ESBB is open for everyone
interested in all aspects of biobanking and biopreservation
of biological resources (human, animal, plant, microbial, and
environmental), including biobank management, QA and
preanalytics, automation, IT solutions, research and innova-
tion, education, ethical, legal, regulatory, and social issues.
Members represent the full spectrum of individuals, academic
institutions, and companies, whereas a substantial part of
members represents clinical-related biorepositories (ESBB;
www.esbb.org). Results of these surveys were used to develop
a strategy document for human sample exchange between
partners as a deliverable of the HBM4EU project. In this
study, we present and discuss the main findings of this
HBM4EU deliverable report D7.2 Strategy and Standard
Operating Procedures (SOPs) for human sample exchange,
including ethical demands.11 To the best of our knowledge, a
comparison of practices applied in HBM-related and clinical
biorepositories was not reported so far. Besides offering in-
sights into differences and similarities, our results may provide
ideas and opportunities for harmonizing and optimizing pro-
cesses in the emerging field of biobanking for HBM purposes.
Materials and Methods
Survey design
A cross-sectional online survey was developed on the
web-based platform LimeSurvey. The survey was accessible
through a link to the online platform for HBM4EU partners
and ESBB members. The cover page of the survey stated the
context of the study, asked for participant’s consent to the
use of the supplied responses, and confirmed anonymous
treatment of participant’s responses. A link to the HBM4EU
survey website was disseminated by email to HBM4EU
partners by the National Hub Contact Point (NHCP) with a
short description of the purpose of the survey, instructions to
forward the link to any HBM4EU repository contact not yet
addressed, and a deadline for completing the survey within a
period of 3 months. A link to the ESBB survey website was
distributed through email to ESBB members by the ESBB
office, with the same instructions as in the case of the
HBM4EU survey. HBM4EU partners and ESBB members
were asked to forward the email specifically to the person
responsible for the operation of the respective biobank.
The survey consisted of 28 closed-form questions in ei-
ther single-choice (SC) or multiple-response (MR) form,
with most questions additionally allowing an open-form
(OF) answer by choosing the option ‘‘other’’ and filling in
free-form text. The survey was structured into six blocks
representing the following topics: Biorepository Back-
ground, Legal and Ethical Considerations, Sample Types
and Aspects of Sample Storage, Sample Shipment, Data
Management, and Quality Management.
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The survey addressed to HBM4EU partners was identical
to the survey for ESBB members, except for the omission of
the block on Biorepository Background, which had already
been included in a previous survey (HBM4EU Task 7.1
survey) completed by 43 biobanks participating in
HBM4EU.12 The previous survey was carried out from
March to the end of May 2017, the HBM4EU and ESBB
surveys were open from September to the end of November
2017. As the study aimed to identify the status quo of HBM-
related biobanks and to compare it with the current state-of-
the-art in biobanking of ESBB members, the block on
Sample Types and Aspects of Sample Storage focused on
the five matrices most relevant in HBM research (whole
blood, plasma, serum, 24-hour urine, and spot urine). Within
this block, questions about storage conditions (temperature,
containers, and duration) were asked once per individual
matrix the participants had stated to store.
Data analysis
Answers to the survey questions were exported in csv
format and read into R (version 3.2.3) for further analysis.
Survey results are presented in the results section in tabular
form ordered by question blocks. For each question, the type
of question (SC, MR, or OF) and the total number of survey
participants the question was presented to are noted in the
table header. The ratio and percentage (in brackets) of sur-
vey participants choosing a given answer are shown in the
body of the table. The number of survey participants not
providing an answer to a given question is noted under the
answer option ‘‘no answer.’’
Results
The following sections detail the results extracted from
the survey responses. The first section describes completion
rates of the survey and the subsequent sections detail the
results of the individual question blocks the surveys were
composed of.
Completion rate
Forty-five responses of distinct biobanks were received
from HBM4EU partners, out of which 36 were considered
valid (seven responses contained answers to less than 30%
of the survey questions and two responders did not agree to
anonymize publication of their supplied data). The 36 valid
responses answered at least 60% of the survey questions
(mean completion rate: 83%). Thirty-two out of the 36 valid
responses were supplied by biobanks that had already par-
ticipated in the previous HBM4EU Task 7.1 survey.12 The
remaining four responses came from HBM4EU-partnered
biobanks that had not been reached by the previous survey.
Twenty-nine responses of distinct biobanks were received
from ESBB members, out of which 28 were valid (one re-
sponder did not agree to anonymize publication of their sup-
plied data). The 28 valid responses answered at least 70% of
the survey questions (mean completion rate: 92%) (Table 1).
Biorepository background
Responses to the surveys indicate that the majority of both,
biorepositories of HBM4EU and biorepositories of ESBB
members who filled in the questionnaire, are hosted by public
institutions (Table 2, Q1). HBM-related biorepositories
identified by this survey are mostly operating within research
institutes, whereas most biorepositories for clinical purposes
are based in hospitals, universities, or research institutes
(Table 2, Q2). The majority of HBM4EU repositories are
operated as a single and individual repository, whereas ESBB
members reported to operate mostly centralized bior-
epositories that store samples from multiple independent
projects (Table 2, Q3). The host institution is most commonly
offering not only biobanking services but also offers related
processes and services ranging from sampling, sample pro-
cessing, and biobanking to the analysis of samples (Table 2,
Q4). A major difference between ESBB and HBM4EU
biorepositories is the target population. Based on the aim to
reveal the actual exposure and its effects on human health,
HBM4EU responses clearly focus on the general population.
In contrast, biorepositories of ESBB members participating
in the survey mainly target samples from patients or clinical
cohorts (Table 2, Q5). As a consequence, the design of their
studies also revealed differences. While HBM studies mostly
follow a cross-sectional or longitudinal study design, in
clinical biorepositories case–control, case-only, and clinical
trial studies are equally well represented (Table 2, Q6). Only
a very small number of HBM4EU partner biorepositories
were members of a biobanking society, for example, of the
ESBB and the International Society for Biological and
Environmental Repositories (ISBER), or participated in the
Biobanking and Biomolecular Resources Research Infra-
structure – European Research Infrastructure Consortium
(BBMRI-ERIC). To gain insight in clinical biobanking, we
addressed the questionnaire to ESBB members. In addition to
ESBB, some of the biorepositories responded to also be a
member of ISBER and/or BBMRI-ERIC (Table 2, Q7).
Legal and ethical considerations
The use of human samples for research purposes postulates
the prior informed consent of the sample donor. This can be
Table 1. Overview of Survey Participation
HBM4EU Task 7.1 survey HBM4EU survey ESBB survey
Number of responses 43 45 29
Insufficient answers (<30% of questions answered) 0 7 0
Agreement to publication of data lacking 0 2 1
Valid responses 43 36 (32/36 biobanks also
surveyed by Task 7.1)
28
ESBB, European, Middle Eastern and African Society for Biopreservation and Biobanking; HBM4EU, European Human Biomonitoring
Initiative.
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Table 2. Biorepository Background
Type of institution
Q1—SC HBM4EU (n = 36) ESBB (n = 28)
Public 34/35 (97%) 24/28 (86%)
Private 1/35 (3%) 4/28 (14%)
Other 0/35 (0%) 0/28 (0%)
No answer 1 0
Host institution of the biorepository
Q2—MR HBM4EU (n = 36) ESBB (n = 28)
Hospital 5/36 (14%) 13/28 (46%)
University 6/36 (17%) 10/28 (36%)
Research institute 20/36 (56%) 13/28 (46%)
Patient’s association 0/36 (0%) 0/28 (0%)
Company 1/36 (3%) 2/28 (7%)
Other 8/36 (22%) 1/28 (4%)
Organizational format
Q3—SC HBM4EU (n = 36) ESBB (n = 28)
Single individual biorepository 23/33 (70%) 4/28 (14%)
Centralized biorepository (storing samples
from multiple independent projects)
8/33 (24%) 21/28 (75%)
Other 2/33 (6%) 3/28 (11%)
No answer 3 0
Carried out activities at the facility/biorepository
Q4—MR HBM4EU (n = 36) ESBB (n = 28)
Sample collection 30/35 (86%) 23/28 (82%)
Sample preparation 26/35 (74%) 25/28 (89%)
Storage 34/35 (97%) 28/28 (100%)
Sample shipment 24/35 (69%) 25/28 (89%)
Analysis 25/35 (71%) 18/28 (64%)
Other 3/35 (9%) 4/28 (14%)
No answer 1 0
Target population of studies from which samples are stored
Q5—MR HBM4EU (n = 43, previous survey) ESBB (n = 28)
General population 42/43 (98%) 11/28 (39%)
Clinical population 3/43 (7%) 23/28 (82%)
Other 5/43 (12%) 3/28 (11%)
Design of studies from which samples are stored
Q6—MR HBM4EU (n = 43, previous survey) ESBB (n = 28)
Cross-sectional 17/42 (40%) 12/28 (43%)
Longitudinal 24/42 (57%) 17/28 (61%)
Case–control 5/42 (12%) 10/28 (36%)
Case-only 0/42 (0%) 13/28 (46%)
Clinical trial 0/42 (0%) 9/28 (32%)
Other 5/42 (12%) 6/28 (21%)
No answer 1 0
Is your institution a registered member of a biobanking society or infrastructure?
Q7—MR HBM4EU (n = 36) ESBB (n = 28)
ESBB 2/36 (6%) 26/28 (93%)
BBMRI-ERIC 3/36 (8%) 10/28 (36%)
ISBER 2/36 (6%) 10/28 (36%)
Other 3/36 (8%) 5/28 (18%)
None 29/36 (81%) 0/28 (0%)
Presented are the type of question (SC; MR), the total number of survey participants, as well as ratio and percentage (in brackets) of
survey participants choosing a given answer. The number of survey participants not providing an answer is noted under ‘‘no answer.’’
The information marked in bold is the most relevant result.
BBMRI-ERIC, the Biobanking and Biomolecular Resources Research Infrastructure – European Research Infrastructure Consortium;
ISBER, International Society for Biological and Environmental Repositories; MR, multiple response question; SC, single choice question.
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either specific and allow only the use of samples for a well-
defined set of analysis or can be broad to allow sample usage
for a much wider range of analyses, even for such analysis
not directly affiliated with the original research question.
Results of our survey indicate specific and broad consents to
be applied in HBM as well as in medical research. Currently,
broad consents seem to be the preferred consent type used
by ESBB-affiliated biorepositories (Table 3, Q1, Q2). We
further asked which legal and ethical documents are avail-
able for the collections. Nearly all ESBB-registered bior-
epositories reported to have ethical approval forms (86%),
informed consent forms (86%), and Material Transfer
Agreements (MTAs, 82%), as well as data protection (57%)
and biobank approvals (68%) available for the majority of
collections. In medical research, MTAs are well-established
tools to ensure legally approved sample exchange, as our
results confirm (Table 3, Q4). However, only 47% of bior-
epositories of the HBM4EU consortium reported the use of
MTAs. Data protection as well as biobank approvals were
also lacking (Table 3, Q3).
Sample types and aspects of sample storage
Sample types. Since whole blood, plasma, serum, 24-hour
urine, and spot urine are often used sample types in HBM,
the block on technical storage aspects focused on these
sample types. Interestingly, besides collecting other sample
types (like e.g., cell isolates, cell lines, and tissues), HBM-
relevant sample types have also been collected by surveyed
biorepositories in the ESBB community (Table 4, Q1).
Furthermore, these samples are usually stored by ESBB
biorepositories using similar supplements as HBM4EU
biorepositories (EDTA or Na/Li-Heparin for whole blood
and plasma samples, no supplement added to serum and
urine samples, data not shown).
Storage infrastructure. Both surveyed groups still use a
wide variety of sample containers (Table 4, Q3). However,
not all containers are suited for cryopreservation of samples
using liquid nitrogen (LIN) as the cooling agent. Therefore,
the use of specific container types indicates widespread
sample storage at temperatures above -130C. In clinical
Table 3. Legal and Ethical Considerations
Type of broad consent
Q1—MR HBM4EU (n = 43, previous survey) ESBB (n = 28)
No broad consent 17/43 (40%) 4/27 (15%)
Written informed consent 25/43 (58%) 22/27 (81%)
Parents’ written consent 17/43 (40%) 10/27 (37%)
Oral consent 1/43 (2%) 2/27 (7%)
Other 0/43 (0%) 5/27 (19%)
No answer 0 1
Type of specific consent
Q2—MR HBM4EU (n = 43, previous survey) ESBB (n = 28)
No specific consent 18/43 (42%) 8/25 (32%)
Written informed consent 24/43 (56%) 15/25 (60%)
Parents’ written consent 15/43 (35%) 5/25 (20%)
Oral consent 0/43 (0%) 1/25 (4%)
Other 0/43 (0%) 5/25 (20%)
No answer 0 3
Which of the following documents are available
Q3—MR HBM4EU (n = 43, previous survey) ESBB (n = 28)
Ethics approval 42/43 (98%) 24/28 (86%)
Informed consent 42/43 (98%) 24/28 (86%)
Data protection approval 0/43 (0%) 16/28 (57%)
Biobank approval 0/43 (0%) 19/28 (68%)
Material transfer agreement 20/43 (47%) 23/28 (82%)
Other 0/43 (0%) 7/28 (25%)
Are terms and conditions for authorized sample usage defined in an MTA?
Q4—SC HBM4EU (n = 36) ESBB (n = 28)
No 11/32 (34%) 2/27 (7%)
Yes 17/32 (53%) 22/27 (81%)
Other 4/32 (13%) 3/27 (11%)
No answer 4 1
Presented are the type of question (SC; MR), the total number of survey participants, as well as ratio and percentage (in brackets) of
survey participants choosing a given answer. The number of survey participants not providing an answer is noted under ‘‘no answer.’’
The information marked in bold is the most relevant result.
MTA, Material Transfer Agreement.
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Table 4. Sample Types and Aspects of Sample Storage
What type of biological samples/matrix do you store?
Q1—MR HBM4EU (n = 36) ESBB (n = 28)
Whole blood 24/34 (71%) 16/26 (62%)
Plasma 24/34 (71%) 21/26 (81%)
Serum 21/34 (62%) 19/26 (73%)
Urine (24 hours) 8/34 (24%) 11/26 (42%)
Urine (spot sample) 23/34 (68%) 9/26 (35%)
Other 11/34 (32%) 20/26 (77%)
No answer 2 2
How long are your samples stored?
Q2—MR HBM4EU (n = 36) ESBB (n = 28)
No storage 0/35 (0%) 1/27 (4%)
Short-term storage 10/35 (29%) 7/27 (26%)
Long-term storage 33/35 (94%) 26/27 (96%)
Other 1/35 (3%) 1/27 (4%)
No answer 1 1
What type(s) of sample container(s) do you use?
(only shown to participants storing HBM-relevant samples)
Q3—MR HBM4EU (n = 34) ESBB (n = 21)
Cryo-vials 13/32 (41%) 15/20 (75%)
Falcon/Corning tubes 10/32 (31%) 3/20 (15%)
Glass tubes/vials 4/32 (13%) 1/20 (5%)
Plates 1/32 (3%) 0/20 (0%)
Plastic bags/containers 3/32 (9%) 0/20 (0%)
Sterile containers 6/32 (19%) 5/20 (25%)
Straws 0/32 (0%) 2/20 (10%)
Tubes of type Eppendorf 8/32 (25%) 2/20 (10%)
Vacutainer 8/32 (25%) 5/20 (25%)
Other 5/32 (16%) 6/20 (30%)
No answer 2 1
At what temperature are samples stored for short-term storage?
(only shown to participants short-term storing HBM-relevant samples)
Q4—MR HBM4EU (n = 25) ESBB (n = 16)
Not applicable 4/25 (16%) 1/16 (6%)
Room temperature 1/25 (4%) 2/16 (12%)
Refrigerator +4C 5/25 (20%) 3/16 (19%)
Freezer -20C 13/25 (52%) 5/16 (31%)
Freezer -80C 9/25 (36%) 13/16 (81%)
LIN, gas phase 0/25 (0%) 4/16 (25%)
LIN, liquid phase 1/25 (4%) 1/16 (6%)
Other 1/25 (4%) 1/16 (6%)
At what temperature are samples stored for long-term storage?
(only shown to participants long-term storing HBM-relevant samples)
Q5—MR HBM4EU (n = 32) ESBB (n = 16)
Not applicable 0/32 (0%) 1/16 (6%)
Room temperature 0/32 (0%) 0/16 (0%)
Refrigerator +4C 0/32 (0%) 0/16 (0%)
Freezer -20C 12/32 (38%) 2/16 (12%)
Freezer -80C 23/32 (72%) 16/16 (100%)
LIN, gas phase 2/32 (6%) 5/16 (31%)
LIN, liquid phase 2/32 (6%) 4/16 (25%)
Other 2/32 (6%) 0/16 (0%)
(continued)
127
biobanking, the use of cryovials is much more common than
in HBM-related biobanking. Long-term storage is of great
importance for the HBM4EU consortium as well as for the
ESBB community (Table 4, Q2). Within the HBM4EU
initiative, most partners (72%) use electrical freezers for
long-term storage at -80C for at least one sample type
(Table 4, Q5). Nevertheless, long-term storage at -20C is
also very prominent (38%). The latter is less common in
ESBB biorepositories (12%), who all use electrical freezers
at -80C for storage of at least one sample type. Thirty-one
percent of ESBB biorepositories additionally operate LIN-
based infrastructures for long-term storage, which allow
storage of samples at temperatures below -130C, while the
percentage of HBM4EU biorepositories capable of storage
in LIN-based systems below -130C is low (6%).
Sample labeling. Barcodes printed on cryo-compatible
labels are widely applied in clinical as well as in HBM
biobanking. However, handwritten labels are still used by
almost a third of the surveyed HBM4EU-affiliated bior-
epositories (Table 4, Q6). Pseudonymization is a procedure
by which the most identifying fields within a data record are
replaced by one or more artificial identifiers, or pseudo-
nyms. The purpose is to render the data record less identi-
fying. The pseudonym allows tracking back of data to its
origins, which distinguishes pseudonymization from anon-
ymization where all person-related data that could allow
backtracking have been purged. Survey responses indicate
that sample labels are either anonymized or pseudonymized
in both communities, HBM4EU and ESBB (Table 4, Q7).
Sample shipment
HBM4EU partners and ESBB members have been ship-
ping nonregulated and/or samples that are classified as
category B samples (Diagnostic specimens, assigned to UN
3373) most frequently (Table 5, Q1). To inform the receiver
before shipment is well established in both surveyed com-
munities (Table 5, Q3). The sample transfer protocol
(manifest) serves as a control sheet and gives a detailed
summary of all samples to be shipped. In the ESBB com-
munity, 87.5% of surveyed biorepositories send a manifest
to prospective sample recipients, whereas only 59% of
HBM4EU-partnered biobanks use manifests (Table 5, Q4).
Where manifests are used, HBM4EU partners and ESBB
members do, however, include a comparable degree of de-
tail (Table 5, Q5). An important parameter for assuring the
sample quality is the recording (logging) of the temperature
during sample shipment. Although some biorepositories of
both communities log the temperature either at sending and
reception or continuously, still 54% of responding ESBB
members and 65% of HBM4EU partners do not log ship-
ment temperature at all (Table 5, Q6).
Data management
The majority of both interviewed communities already
use a data management system—either by a homemade
solution or a database with respective management software
(Table 6, Q1). Most of the HBM4EU partners (54%) use
homemade solutions (e.g., Excel sheets) for the documen-
tation of sample-linked data, whereas the majority of ESBB
members (75%) store these data in professional databases.
Aside from the technical implementation of sample man-
agement systems, the degree of detail stored about a sam-
ple’s history is an important parameter as well. Table 6, Q2,
displays the percentage to which individual sample history
items are collected and stored by surveyed HBM4EU and
ESBB biorepositories. Currently, the sampling year, the
date of sample receipt at the repository, the source of the
sample, and the storage temperature are consistently stored
by most surveyed biobanks. A very high proportion of sur-
veyed ESBB biorepositories reported to record all of the
items on sample history included in the survey question (for
details see Table 6, Q2). A more differentiated picture
emerges in HBM biobanking, where individual aspects with
high relevance for QA (e.g., total storage duration, thaw and
Table 4. (Continued)
Design of the primarily used sample label
Q6—SC HBM4EU (n = 36) ESBB (n = 28)
Handwritten 11/36 (31%) 2/28 (7%)
Registration number 12/36 (33%) 5/28 (18%)
1D barcode 10/36 (28%) 12/28 (43%)
Data matrix 2/36 (6%) 6/28 (21%)
QR code 1/36 (3%) 2/28 (7%)
Other 0/36 (0%) 1/28 (4%)
Sample label ensures data protection/privacy through .
Q7—SC HBM4EU (n = 36) ESBB (n = 28)
Anonymization 20/33 (61%) 12/28 (43%)
Pseudonymization 13/33 (39%) 14/28 (50%)
Other 0/33 (0%) 2/28 (7%)
No answer 3 0
Presented are the type of question (SC; MR), the total number of survey participants, as well as ratio and percentage (in brackets) of
survey participants choosing a given answer. The number of survey participants not providing an answer is noted under ‘‘no answer.’’
The information marked in bold is the most relevant result.
1D, one dimensional; HBM, human biomonitoring; LIN, liquid nitrogen.
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Table 5. Sample Shipment
What type of samples do you regularly exchange with other institutions?
Q1—MR HBM4EU (n = 36) ESBB (n = 28)
Nonregulated samples 16/30 (53%) 12/24 (50%)
Category B samples 16/30 (53%) 14/24 (58%)
Category A samples 1/30 (3%) 2/24 (8%)
Other 1/30 (3%) 1/24 (4%)
No answer 6 4
What packaging do you use?
Q2—MR HBM4EU (n = 36) ESBB (n = 28)
Compliant with PI 620 1/24 (4%) 3/21 (14%)
Compliant with PI 650 12/24 (50%) 14/21 (67%)
Compliant with PI 650 light 1/24 (4%) 4/21 (19%)
Compliant with PI 959 1/24 (4%) 4/21 (19%)
Regular parcel 8/24 (33%) 7/21 (33%)
Other 3/24 (13%) 2/21 (10%)
No answer 12 7
Do you inform the recipient before sample shipment?
Q3—SC HBM4EU (n = 36) ESBB (n = 28)
Yes 29/30 (97%) 24/24 (100%)
No 1/30 (3%) 0/24 (0%)
No answer 6 4
Do you send an electronic manifest to the recipient before sample shipment?
Q4—SC HBM4EU (n = 36) ESBB (n = 28)
Yes 16/27 (59%) 21/24 (87.5%)
No 11/27 (41%) 3/24 (12.5%)
No answer 9 4
What information does this manifest include?
(only participants answering Q4 with yes)
Q5—MR HBM4EU (n = 16) ESBB (n = 21)
Name and contact details of shipper 15/16 (94%) 19/20 (95%)
Name and contact details of recipient 13/16 (81%) 17/20 (85%)
Shipping temperature 10/16 (62%) 15/20 (75%)
Date of sample shipment 14/16 (88%) 18/20 (90%)
Biological substance category 9/16 (56%) 11/20 (55%)
Sample type 15/16 (94%) 20/20 (100%)
Sample ID 13/16 (81%) 20/20 (100%)
Sample volume 12/16 (75%) 19/20 (95%)
Type of sample container 5/16 (31%) 10/20 (50%)
Number of samples and/or aliquots 15/16 (94%) 19/20 (95%)
Prior informed consent 2/16 (12%) 5/20 (25%)
Material transfer agreement 6/16 (38%) 11/20 (55%)
Other 1/16 (6%) 1/20 (5%)
No answer 0 1
How do you log sample temperature when shipping samples
Q6—MR HBM4EU (n = 36) ESBB (n = 28)
No logging 20/31 (65%) 14/26 (54%)
Continuous logging 7/31 (23%) 9/26 (35%)
Logging at sending and reception 6/31 (19%) 6/26 (23%)
No answer 5 2
Presented are the type of question (SC; MR), the total number of survey participants, as well as ratio and percentage (in brackets) of
survey participants choosing a given answer. The number of survey participants not providing an answer is noted under ‘‘no answer.’’
The information marked in bold is the most relevant result.
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Table 6. Data Management
What data management system for documentation
of withdrawal/adding of samples do you use?
Q1—SC HBM4EU (n = 36) ESBB (n = 28)
Homemade solution (e.g., Excel sheets) 19/35 (54%) 7/28 (25%)
Database and respective management software 12/35 (34%) 21/28 (75%)
No data management system 4/35 (11%) 0/28 (0%)
No answer 1 0
What information about a stored samples history do you record?
Q2—MR HBM4EU (n = 36) ESBB (n = 28)
No information 1/35 (3%) 0/28 (0%)
Source of the sample 27/35 (77%) 24/28 (86%)
Date of sample receipt at the repository 29/35 (83%) 28/28 (100%)
Date of sample shipment from the repository 16/35 (46%) 24/28 (86%)
Total storage duration 18/35 (51%) 22/28 (79%)
Sampling year/sampling period 31/35 (89%) 22/28 (79%)
Person in charge 20/35 (57%) 18/28 (64%)
Storage temperature 25/35 (71%) 26/28 (93%)
Thaw and refreezing cycles 8/35 (23%) 20/28 (71%)
Subaliquots 15/35 (43%) 21/28 (75%)
Deviations (e.g., interruption of cooling chain) 11/35 (31%) 18/28 (64%)
Other 2/35 (6%) 4/28 (14%)
No answer 1 0
Presented are the type of question (SC; MR), the total number of survey participants, as well as ratio and percentage (in brackets) of
survey participants choosing a given answer. The number of survey participants not providing an answer is noted under ‘‘no answer.’’
The information marked in bold is the most relevant result.
Table 7. Quality Management
Is your institution certified, accredited, or otherwise qualified in a quality management system?
Q1—SC HBM4EU (n = 36) ESBB (n = 28)
No 18/34 (53%) 12/28 (43%)
Yes 16/34 (47%) 16/28 (57%)
No answer 2 0
Please specify according to which norm(s)/systems your institution is certified/accredited
or otherwise qualified (only shown to participants answering Q1 with yes)
Q1A—OF HBM4EU (n = 16) ESBB (n = 16)
ISO 9001 8/16 (50%) 12/16 (75%)
ISO 17025 9/16 (56%) 2/16 (13%)
GCP/GLP 0/16 (0%) 5/16 (31%)
ISO 15189 1/16 (6%) 2/16 (13%)
NFS 96–900 1/16 (6%) 1/16 (6%)
ISO 15025 1/16 (6%) 0/16 (0%)
ISO 14001 0/16 (0%) 1/16 (6%)
ISO 18001 0/16 (0%) 1/16 (6%)
For which activities has a quality management system been established
(only shown to participants answering Q1 with yes)
Q2—MR HBM4EU (n = 16) ESBB (n = 16)
Sampling 8/14 (57%) 13/16 (81%)
Distribution 4/14 (29%) 11/16 (69%)
Shipment 4/14 (29%) 12/16 (75%)
Data management/IT 6/14 (43%) 12/16 (75%)
Processing 11/14 (79%) 15/16 (94%)
Infrastructure 6/14 (43%) 13/16 (81%)
Storage 13/14 (93%) 16/16 (100%)
No answer 2 0
Presented are the type of question (SC; OF; MR), the total number of survey participants, as well as ratio and percentage (in brackets) of
survey participants choosing a given answer. The number of survey participants not providing an answer is noted under ‘‘no answer.’’
OF, open-form question.
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refreeze cycles, and deviations) are recorded by 51% or less
of the surveyed biorepositories (Table 6, Q2).
Aspects of quality management
Only 16 out of the 34 HBM4EU-partnered biorepositories
providing an answer (47%) have already established a quality
management system. Furthermore, out of those 16, only 4
(25%) established a quality management system for sample
distribution and sample shipment. Fifty-seven percent of
surveyed ESBB members responded that they have estab-
lished quality management systems (Table 7, Q1). The norms
applied most commonly by HBM-related repositories are DIN
EN ISO 9001 and DIN EN ISO/IEC 17025. Clinical reposi-
tories additionally apply GCP-/GLP-based QMS (Table 7,
Q1A). Table 7, Q2, details the survey regarding establishment
of quality management for different biobanking-related ac-
tivities. In general, quality management and control measures
appear to be implemented to a greater extent at ESBB bior-
epositories.
Discussion
HBM-related biorepositories differ from repositories for
clinical research in many aspects. as confirmed by our re-
sults. The most prominent differences are highlighted in
bold in Tables 1 to 7. Briefly, HBM-related biorepositories
in most cases are based at public research institutes, orga-
nized as single/individual biorepository with samples only
for the purpose of revealing the exposure to environmental
pollutants, and hence, focus on cross-sectional or longitu-
dinal studies with samples from the general population. In
contrast, ESBB members report clinical-related bior-
epositories to be mostly based in hospitals or public research
institutes, organized as centralized facilities with samples
from multiple independent projects. Due to the clinical ap-
proach, case–control, case-only, and clinical trial studies are
equally well represented and samples from patients or
clinical cohorts are in focus. This implies differences in
technical and operational details (e.g., differences in storage
temperature, sample container, sample labeling, and data
management). Although the purpose of clinical bior-
epositories differs from HBM-related biorepositories, there
are overlaps in quality requirements and biobanking pro-
cesses, and thus, harmonization and standardization are
crucial in both areas of application. Large efforts have al-
ready been undertaken to harmonize biobanking-related
processes and procedures, including ethical and legal as-
pects in biobanking for medical research across Europe as
well as globally.13–15 General guidelines are provided by
ISBER in the ISBER Best Practices16 and the Organisation
for Economic Co-operation and Development (OECD)
guidelines on human biobanks and genetic research data-
bases.17 In Europe, the planning phase of BBMRI was al-
ready initiated in 2008,18,19 and evolved into an European
Research Infrastructure Consortium (ERIC) in the following
years. BBMRI-ERIC aims at providing access to biobanks
of different formats, harmonizing standards, establishing
operational procedures, including ethical, legal, and societal
aspects, and securing sustainable funding for European
biobanks.19,20 Since 2011, ESBB has been providing a sci-
entific platform for knowledge exchange in the biobanking
field and as scientific society has been vitally supporting
biosharing on a European scale through mobilizing, inspir-
ing, and educating. Interestingly, the majority of HBM4EU
partners are not registered as member of a biobanking so-
ciety (e.g., ESBB and ISBER) or research infrastructure
(BBMRI-ERIC). Knowledge exchange between these
communities, however, is vital and participation in such
societies provides access to standards and best practices in
biobanking, promoting harmonization in this area. Despite
controversial discussions on harmonization in health-related
biobanking and the many aspects in biobanking that have to
be considered,14,15,21,22 harmonization has, in many cases,
been achieved or substantial efforts are in progress. Al-
though many requirements are already met by HBM4EU
partners, there is still a need for improvement regarding
some legal and technical issues. Ethical and legal aspects
build the basic framework for the usage of human samples.
The consent given by the sample donor sets the scene in
research and defines boundaries or opens doors. In HBM
research, a specific consent limiting use of samples to the
analysis of the addressed environmental pollutants has been
considered sufficient for decades. In medical research,
consent forms allowing a broader use of samples are dis-
cussed intensively, especially since interoperability between
biobanks and researchers requires exchange and sharing of
high-quality samples and data to manage the various chal-
lenges in today’s biomedical research.23,24 A key point for
elevating HBM in Europe to the next level will be the
combination of health and HBM surveys to share expertise,
transfer knowledge, and jointly use available samples and
associated data, while aiming at a better understanding of
the impact of environmental stressors on human health. How
beneficial such a combination can be is demonstrated by the
various outcomes of the National Health and Nutrition Ex-
amination Survey (NHANES) conducted regularly by the
U.S. Centers for Disease Control and Prevention (CDC).25
Combining both survey types on a European scale will
generate valuable data that are urgently needed as the sci-
entific basis for a political regulation pertaining to the use of
harmful chemicals in Europe. Recently, two internal feasi-
bility studies were started in HBM4EU, with the aim to test
the possibility of integrating HMB modules in health sur-
veys (LIFE, Germany; KuoBio, Finland) and to investigate
if already collected samples might be suitable for HBM
research. Interestingly, our survey results revealed that rel-
evant sample types required for HBM analysis are also
stored in clinical repositories of ESBB members. Samples
might be stored in different sample containers, in different
volumes, and at different temperatures. Whether theses
samples are suitable to support HBM activities in Europe
and their exchange between both communities is legally
acceptable need further investigation. In any case, particu-
larly for sample exchange and interdisciplinary sample us-
age, the donor has to consent accordingly. HBM4EU hence
can benefit from experience and knowledge already gained
by clinical biobanks with regard to the handling and im-
plementation of broad consents. Often, the required legal
framework, for example, sample exchange between a study
owner (biobank) and third parties (e.g., researches and
laboratories), is not clear, since different regulation mech-
anisms might apply, especially between different countries.
The implementation of the General Data Protection Reg-
ulation (GDPR) in May 2018 even increased complexity,
since the exchange of samples in most cases is accompanied
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by personal data as defined in Article 4 of GDPR. A valu-
able tool to guarantee legally approved exchange of samples
is MTAs or Material and Data Transfer Agreements
(MDTAs). They define the terms and conditions under
which samples and associated data can be transferred and
used.26–29 However, terms and conditions defined in an
MTA have to comply with the consent given by the sample
donor. Minimum requirements on MTAs/MDTAs are de-
fined in the ISBER Best Practices. Since our survey revealed
a limited use of MTAs among HBM4EU partners, an
MDTA has been developed jointly with a strategy document
for harmonized sample exchange within HBM4EU. This
MDTA is publicly available for download in the online li-
brary of the official HBM4EU homepage (https://www
.hbm4eu.eu/). Briefly, general terms and conditions are de-
fined in a HBM4EU master MDTA. As pseudonymized data
will be exchanged with any material transfer within
HBM4EU, the HBM4EU MDTA also includes a data con-
troller/data processor agreement to comply with the re-
quirements on data exchange and usage of the GDPR. This
integrated agreement governs the transfer and processing of
the material-associated pseudonymized data. A second
document, the HBM4EU Material and associated Data
Transfer Record Form (HBM4EU MDTRF), is used to
specify the general terms and conditions of the HBM4EU
master MDTA and to document each individual transfer of
material between material and data provider and recipient.
With the signing of this form by both parties, the terms and
conditions defined in the HBM4EU master MDTA and
specified in the HBM4EU MDTRF, including the data
controller/data processor agreement, are accepted.
Besides these ethical and legal aspects, biomedical re-
search as well as HBM demand a certain level of sample
quality. Experiences in medical research revealed the sig-
nificant impact of variations in preanalytical steps, including
sample storage and shipment on various sample compo-
nents.30–35 With regard to HBM-relevant chemicals, single
studies confirm that preanalytical steps may alter sample
components of interest too.36–38 Within HBM4EU, stan-
dardized protocols are already available for sampling and
sample preparation. In addition, several ISO norms are
available for a standardized sample preparation. High-quality
genomic DNA, RNA, proteins, and related state-of-the-art
methods (e.g., whole-genome sequencing and single-cell
sequencing) are becoming more and more important for the
development of new biomarkers of effect and to identify
methylation patterns and epigenetic alterations related to
chemical exposure.39–42 In consequence, adopting the ISO
20186 and ISO 20184 series for a standardized isolation of
RNA, DNA, and proteins from fresh and frozen samples
would be most valuable for the HBM4EU community.
Standards for tissues uncommon for use in HBM are addi-
tionally available, for example, formalin-fixed tissues (ISO
20166 series), which may be relevant in the future. Differ-
ences in sample handling, preparation, and storage between
both communities can be explained by the different aims.
Currently, HBM focuses on the analysis of chemicals in hu-
man samples, while clinical research deals with the analysis
of highly labile molecules, for example, DNA, RNAs, pro-
teins, metabolites, and hormones.
Pertaining to sample exchange, important aspects have
been condensed into a strategy document and an accompa-
nying HBM4EU SOP facilitating sample exchanges between
HBM4EU partners (https://www.hbm4eu.eu/deliverables/,
Deliverable 7.2). However, not much focus was put on the
harmonization of storage conditions in HBM studies across
Europe yet. Results indicate a wide variety of storage tem-
peratures are used predominantly by the HBM4EU partners.
In the context of medical research, it has been proven that
different storage temperatures and temperature fluctuations
during storage impact sample integrity with regard to bio-
markers of interest.30,43–46 The impact of storage conditions
has also been demonstrated in cases of individual HBM-
relevant substances, for example, polychlorinated biphenyls,
brominated flame retardants, some pesticides, or arsenic
species.36,47 It is therefore reasonable to assume that other
environmental pollutants might be equally affected by dif-
ferent storage conditions. To provide high-quality samples,
especially pertaining to DNA, RNA, or cell lines, long-term
storage requires temperatures below the glass transition
temperature.48 To consistently support reproducibility,
compliance, and robustness of HBM sample storage, har-
monization and standardization and related biobanking pro-
cesses on a European level are a prerequisite. Only the
availability of high-quality and comparable samples will
guarantee the generation of reliable and comparable analyt-
ical results. Due to the relatively high investment needed to
install LIN-based storage technologies, not every partner
within HBM4EU might be able to realize storage conditions
to protect samples from alteration as far as possible. Since
compatibility of the samples has to be guaranteed, it is re-
commended to document and harmonize storage conditions
between HBM4EU partners for long-term storage to at least
-80C or lower. Besides storage temperature, the shipping of
the samples should also be harmonized. To secure high
quality of samples through maintaining low temperatures
during shipment, it is recommended to ship all frozen samples
on dry ice within HBM4EU and to continuously record the
shipping temperature with either a temperature logger or al-
ternatively to measure the temperature of the sample before
shipment, and on receipt, to confirm temperature mainte-
nance. Moreover, to increase comparability of newly col-
lected samples in HBM4EU, centralized national storage
facilities as national hubs of a European Biobank for HBM
samples (HBM4EU Biobank) could be established at
HBM4EU partner or third linked party sites at which a re-
quired LIN-based infrastructure is already available and
which could be expanded with reasonable expenditure. This
certainly includes many ethical and legal challenges, which
still have to be identified and targeted, especially with regard
to data protection. National hubs could act as quality-
controlled centralized backup facilities at which samples can
be stored and distributed when defined standards of HBM4EU
are not met by single institutions. Similar European and global
biobanks are already established for other research pur-
poses.49,50 In addition, such facilities could provide training
and capacity building for regional institutions and technology
transfer to the HBM4EU consortium. In this context, QA and
quality management could doubtlessly improve sample quality
and effectiveness of collaborations between researchers in
biomedical research and HBM.23,51 QA is an effort to con-
tinuously improve processes to generate high-quality samples
with comparable and reliable data. Key components of QA are
management structures, clearly defined workflows described
in SOPs or operation instructions, a transparent documentation
of processes and deviations, and a regular evaluation of the
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established QA measures. QA should already start at the first,
preanalytical steps, including sample collection. In this con-
text, the Biospecimen Reporting for Improved Study Quality
guidelines (BRISQ) as a tool for documenting and reporting
preanalytical factors might be beneficial for HBM research.52
In addition, the ISBER Biospecimen Science Working Group
has developed the standard preanalytical code (SPREC) to
facilitate documentation and communication of the most
important preanalytical quality parameters of different types
of biospecimens used in biomedical research.53–55 This code
system was specifically developed for the use in biomedical
research, and is therefore rarely applied in HBM studies. To
document the quality of a human sample in terms of viability,
functionality, structural integrity, and stability, documenta-
tion of sample-associated data as well as data related to
sample exchanges is essential. In particular, the sample an-
notation by unique identifier and labels as well as the history
tracking of sample-associated events, such as, for example,
shipments or processing steps, play a central role in data
management and transfer. Adaptation of tools like BRISQ and
SPREC to HBM needs, and their integration into HBM-
related biobanking processes thus have the potential to foster
harmonization of HBM efforts. Considering QM systems and
related norms, our results revealed that the norms applied
most commonly are DIN EN ISO 9001, DIN EN ISO/IEC
17025, DIN EN ISO 15189, and GCP/GLP. These norms are
not focused on biobanking in particular, but rather focus on
management structures in general (ISO 9001), testing and
calibration laboratories (ISO 17025), medical laboratories
(ISO 15189), and clinical, respectively, laboratory practice.
Since 2017, general requirements on biobanking are de-
fined in the ISO 20387 norm.56,57 Most institutions that
operate a biorepository for HBM purposes are not medical
or testing and calibration laboratories, but environmental
medical, occupational medical, or toxicological institutes,
which operate their repository mainly to support their main
occupation. To standardize and harmonize QA/QC activi-
ties pertaining to biobanking within HBM4EU, HBM4EU
institutions that collect, store, and distribute samples
should implement the requirements of ISO 20387. This will
allow a certification of a QA/QC system specifically and
solely for biobanking processes without interfering with
other processes operated by the institution, e.g., environ-
mental analysis, which might require a different level of
QA/QC.
Although valuable information is gained, the conducted
survey shows some limitations. As the survey is aimed at
HBM4EU partners, it was carried out, in part, to identify
biorepositories within the initiative that collect and store
samples for the purpose of HBM; therefore, the link to the
questionnaire was spread through the HBM4EU community,
resulting in an unknown number of recipients. In the case of
the survey addressed to ESBB members, the instructions in
the email sent out also included a request for forwarding the
mail to contacts responsible for the operation of bior-
epositories. In addition, while we sent out the survey to all
ESBB members, not all ESBB members represent a clinical
biobank. Hence, in both cases, the total number of bior-
epositories addressed is unknown and so the response rate is
lacking. Nevertheless, with the reasonable number of re-
ceived responses, the intention of this survey, gaining gen-
eral insights into biobanking processes at the two surveyed
types of repositories, should be fulfilled.
Conclusion
Besides analytics, biobanking is a valuable component of
HBM research, since more and more samples are needed to
compare exposure levels between European countries over
time. The term biobanking, however, does not only describe
sample storage but also includes a variety of processes, for
example, sample reception, handling, and shipment. Taken
together, these biobanking-related preanalytical processes
play an important role with regard to sample quality, and
hence, in the particular case of HBM with regard to the
comparability and reliability of chemical analytical results.
In these preanalytical processes, the conducted survey
identified many similarities between ESBB-affiliated and
HBM4EU-partnered biorepositories. Nevertheless, a need
for harmonization was identified for some processes in
sample storage, shipment, and related data management.
The full harmonization of biobanking activities between
European countries for HBM purposes is a challenging task.
However, to reach a reasonable minimum in harmonization,
some important aspects, for example, pertaining to sample
and associated data exchange, have been addressed within
the HBM4EU initiative. In the context of standardizing
sample storage for HBM purposes, although, some questions
still remain unanswered. Empirical data, especially on long-
term stability of exposure biomarkers and the impact of
different storage temperatures on sample integrity, would be
helpful. An engagement of the HBM4EU initiative with key
organizations in biobanking, such as ESBB, ISBER, and
BBMRI-ERIC, can further enhance harmonization of ac-
tivities and create higher visibility for both biobanking and
HBM in Europe.
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for Europe. Brief Bioinform 2008;9:14–24.
16. Campbell LD, Astrin JJ, DeSouza Y, et al. The 2018 re-
vision of the ISBER Best Practices: Summary of changes
and the editorial team’s development process. Biopreserv
Biobank 2018;16:3–6.
17. OECD. OECD guidelines on human biobanks and genetic
research databases. Eur J Health Law 2010;17:191–204.
18. Wichmann HE, Kuhn KA, Waldenberger M, et al. Com-
prehensive catalog of European biobanks. Nat Biotechnol
2011;29:795.
19. Viertler C, Zatloukal K. [Biobanking and Biomolecular
Resources Research Infrastructure (BBMRI). Implications
for pathology]. Pathologe 2008;29 Suppl 2:210–213.
20. van Ommen G-JB, Törnwall O, Bréchot C, et al. BBMRI-
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